6.01
+4.34%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Hisoar Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002099.SZ. It has been listed since 26 December 2006. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.86bn and a net loss of CN¥91.1m. At that date it held total assets of CN¥7.33bn and shareholders' equity of CN¥5.04bn.
Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the production of active pharmaceutical ingredients and fine chemicals. The company is headquartered in Taizhou, Zhejiang. The company went IPO on 2006-12-26. is a China-based company principally engaged in the manufacture and sale of pharmaceutical materials and dyes. The firm operates through two segments: Pharmaceutical segment and Dye segment. Pharmaceutical segment manufactures and sells Active Pharmaceutical Ingredients (APIs) and preparations, as well as provides customized production and supporting research and development services for international pharmaceutical companies. The Company’s pharmaceutical products comprise antibiotic series, hypoglycemic series and cardiovascular series. Dye segment is mainly involved in the manufacture and sale of environmentally friendly reactive dyes, dye intermediates and pigment intermediates. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Dec 2006
- Employees
- 2,788
- Website
- hisoar.com ↗
Leadership
Pay as last reported
- Mr. Yangchao WangChairman of the Board, since 2019CN¥608,000
- Mr. Bing YaoChief Financial Officer, Deputy General Manager, Director, since 2019CN¥1.0m
- Mr. Guorui XuGeneral Manager, Director, since 2014CN¥1.0m
- Mr. Wenhua MaoDeputy General ManagerCN¥600,800
- Mr. Kang YanSecretary of the Board
- Ms. Hong TaoDirectorCN¥604,400
- Ms. Chao LiangIndependent DirectorCN¥80,000
- Mr. Jianmin QianIndependent DirectorCN¥80,000
- Mr. Yongping YuIndependent DirectorCN¥80,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 52
- Environment
- 51
- Social
- 49
- Governance
- 58
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Hisoar Pharmaceutical Co Ltd operates through two distinct segments: the Pharmaceutical segment and the Dye segment.
- The Pharmaceutical segment manufactures and sells Active Pharmaceutical Ingredients (APIs) and preparations for international clients.
- The company employs 2,788 full-time staff members to support its production and research activities.
Weaknesses
- The company is headquartered in Taizhou, Zhejiang, which limits its operational base to a single city.
- Zhejiang Hisoar Pharmaceutical Co Ltd is listed on the Shenzhen Stock Exchange under ticker 002099.SZ, restricting its primary market access.
- The firm's product portfolio is confined to antibiotic, hypoglycemic, and cardiovascular series within the pharmaceutical sector.
Opportunities
- The Dye segment manufactures environmentally friendly reactive dyes, which aligns with growing global sustainability demands.
- The company provides customized production and supporting research and development services for international pharmaceutical companies.
- Zhejiang Hisoar Pharmaceutical Co Ltd distributes its products to overseas markets, expanding beyond its domestic base.
Threats
- The company is subject to regulatory frameworks in China, where it is incorporated under ISIN CNE000001PY2.
- Zhejiang Hisoar Pharmaceutical Co Ltd competes in the Health Care sector, which faces intense global pricing pressures.
- The firm relies on the manufacture and sale of fine chemicals, a segment vulnerable to raw material price volatility.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.